Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality

Bibliography

• Ferri CP, Prince M, Brayne C, Global prevalence of dementia: a Delphi consensus study. Alzheimer's Disease International. Lancet 2005;366:2112-17
   PubMed Web of Science ®Google Scholar
• Steinberg M, Shao H, Zandi P, Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psych 2008;23:170-7
   PubMed Web of Science ®Google Scholar
• Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. IV. Disorders of Behaviour. Br J Psychiatry 1990;157:86-94
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Steinberg M, Tschanz JT, Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-14
   PubMed Web of Science ®Google Scholar
• Margallo-Lana M, Swann A, O'Brien J, Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001;16:39-44
   PubMed Web of Science ®Google Scholar
• The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services by Professor Sube Banerjee; 2009. Available from: ww.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_108302.pdf
   Google Scholar
• Information for Healthcare Professionals: Conventional Antipsychotics FDA ALERT [16 June 2008]. Available from: ww.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm124830.htm
   Google Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93
   PubMed Web of Science ®Google Scholar
• Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 1999;1413:267-78
   Google Scholar
• Ballard C, Piggott M, Johnson M, Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-76
   PubMed Web of Science ®Google Scholar
• Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006;7:492-500
   PubMed Web of Science ®Google Scholar
• Sultzer DL, Davis SM, Tariot PN, Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008;165:844-54
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210
   PubMed Web of Science ®Google Scholar
• Mintzer JE, Tune LE, Breder CD, Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007;15:918-31
   PubMed Web of Science ®Google Scholar
• Zhong KX, Tariot PN, Mintzer J, Quetiapine to treat agitation in dementia: a randomized double-blind placebo controlled study. Curr Alzheimer Res 2007;4:81-93
   PubMed Web of Science ®Google Scholar
• Paleacu D, Barak Y, Mirecky I, Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry 2008;23:393-400
   PubMed Web of Science ®Google Scholar
• Ballard C, Margallo-Lana M, Juszczak E, Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial. BMJ 2005;330:874
   PubMed Web of Science ®Google Scholar
• Cohen-Mansfield J, Lipson S, Werner P, Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 1999;159:1733-40
   PubMed Web of Science ®Google Scholar
• Ballard CG, Margallo-Lana M, Fossey J, A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry 2001;62:631-6
   PubMed Web of Science ®Google Scholar
• Schneider LS, Tariot PN, Dagerman KS, CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38
   PubMed Web of Science ®Google Scholar
• Ballard C, Lana MM, Theodoulou M, Investigators DART AD. A randomized, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008;5:76
   PubMed Web of Science ®Google Scholar
• Ballard C, Hanney ML, Theodoulou M, DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol 2009;8:151-7
   PubMed Web of Science ®Google Scholar
• Ballard CG, Thomas A, Fossey J, A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004;65:114-19
   PubMed Web of Science ®Google Scholar
• Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatry Clin N Am 1991;14:353-73
   PubMed Web of Science ®Google Scholar
• Lipscombe L, Levesque L, Gruneir A, Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med 2009;169:1282-9
   PubMed Web of Science ®Google Scholar
• Herrmann N, Mamdani M, Lanctot KL, Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004;161:1113-15
   PubMed Web of Science ®Google Scholar
• Liperoti R, Gambassi G, Lapane KL, Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psych 2005;66:1090-6
   Web of Science ®Google Scholar
• Kleijer BC, van Marum RJ, Egberts AC, Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Psychiatry 2009;23:909-14
   Google Scholar
• Deaths with antipsychotics in elderly patients with behavioral disturbances. US Food and Drug Administration, FDA Public Health Advisory, Centre for Drug Evaluation and Research. FDA; 13 July 2005
   Google Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43
   PubMed Web of Science ®Google Scholar
• Kales HC, Valenstein M, Kim HM, Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007;164:1568-76
   PubMed Web of Science ®Google Scholar
• Hollis J, Grayson D, Forrester L, Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2007;15:932-41
   PubMed Web of Science ®Google Scholar
• Wang PS, Schneeweiss S, Avorn J, Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41
   PubMed Web of Science ®Google Scholar
• Trifiro G, Gambassi G, Sen EF, Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case–control study. Ann Intern Med 2010;152:418-25
   PubMed Web of Science ®Google Scholar
• Knol W, van Marum RJ, Jansen P, Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008;56:661-6
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Wang PS, Alan Brookhart M, Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008;56:1644-50
   PubMed Web of Science ®Google Scholar
• Liperoti R, Onder G, Lapane KL, Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case–control study. J Clin Psychiatry 2008;68:929-34
   Web of Science ®Google Scholar
• Liperoti R, Gambassi G, Lapane KL, Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 2005;165:696-701
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
   PubMed Web of Science ®Google Scholar
• Liperoti R, Pedone C, Lapane KL, Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005;165:2677-82
   PubMed Web of Science ®Google Scholar
• Holmes C, Smith H, Ganderton R, Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry 2001;71:777-9
   PubMed Web of Science ®Google Scholar
• Craig D, Hart DJ, Carson R, Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neurosci Lett 2004;368:33-6
   PubMed Web of Science ®Google Scholar
• Holmes C, Arranz MJ, Powell JF, 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 1998;7:1507-9
   PubMed Web of Science ®Google Scholar
• Sweet RA, Pollock BG, Sukonick DL, The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behaviour in Alzheimer disease. Int Psychogeriatr 2001;13:401-9
   PubMed Web of Science ®Google Scholar
• Pritchard AL, Pritchard CW, Bentham P, Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord 2007;24:201-6
   PubMed Web of Science ®Google Scholar
• Ballard CG, Gauthier S, Cummings JL, Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurosci 2009;5:245-55
   Web of Science ®Google Scholar
• Angelucci F, Bernadini S, Gravina P, Delusion symptomes and response to antipsychotic treatment are associates with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's diseases: a 3-year follow-up longitudinal study. J Alzheimer Dis 2009;17:203-11
   PubMed Web of Science ®Google Scholar
• Dombrovski Y, Mulsanta BH, Ferrell R, Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol 2010;25:37-45
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341-8
   PubMed Web of Science ®Google Scholar
• Chenoweth L, King MT, Jeon YH, Caring for Aged Dementia Care Resident Study (CADRES) of person-centered care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol 2009;8:317-25
   PubMed Web of Science ®Google Scholar
• Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci 2007;62:908-16
   PubMed Web of Science ®Google Scholar
• Ballard C, Brown R, Fossey J, Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). Am J Geriatr Psychiatry 2009;17:726-33
   PubMed Web of Science ®Google Scholar
• Fossey J, Ballard C, Juszczak E, Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 2006;332:756-8
   PubMed Web of Science ®Google Scholar
• Pollock BG, Mulsant BH, Rosen J, A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15:942-52
   PubMed Web of Science ®Google Scholar
• Howard RJ, Juszczak E, Ballard CG, Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357:1382-92
   PubMed Web of Science ®Google Scholar